Treatment Algorithms for Hormone Receptor-Positive Advanced Breast Cancer: Applying the Results from Recent Clinical Trials into Daily Practice—Insights, Limitations, and Moving Forward Treating ...
Efficacy and safety of neoadjuvant docetaxel, carboplatin, trastuzumab/pertuzumab [TCH-P] in non-metastatic HER2+ breast cancer: The Cleveland Clinic experience. This ...
International consensus on the environmental regulatory assessment of endocrine disrupting substance
Results of the SETAC Pellston Workshop "Environmental Hazard and Risk Assessment Approaches for Endocrine-Active Substances" (EHRA) were recently published in Integrated Environmental Assessment and ...
Asal Shirazi, Founder of ASA Foundation, shares insights into what drives inflammatory responses, including the role of ...
Abstract: Variation in endocrine pathways can be a major mechanism underlying life‐history evolution. Yet it is unclear whether this insight, derived primarily from solitary species, explains the ...
(Beyond Pesticides, February 5, 2024) Public Comment Period Ends February 26, 2024. The U.S. Environmental Protection Agency (EPA) never completed protocol for testing pesticides that disrupt the ...
In some cases, HR-positive/HER2-negative breast cancers may over time become resistant to endocrine therapy. This can occur through mutations in the estrogen receptor ...
Growing concerns about environmental contaminants associated with adverse developmental, reproductive, neurological, and immune effects led Congress more than 20 years ago to direct the U.S.
A team of scientists at the Garvan Institute of Medical Research has discovered that inactivation of a stress pathway makes ER+ breast cancer cells ignore stress signals, allowing them to evade ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback